HTBX - ヒ―ト・バイオロジクス （Heat Biologics Inc.） ヒ―ト・バイオロジクスHTBXのチャート
HTBXの企業情報
| symbol | HTBx |
|---|---|
| 会社名 | Heat Biologics Inc （ヒ―ト・バイオロジクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ヒート･バイオロジクス(Heat Biologics Inc.)は開発段階のバイオ医薬品会社であり、多様な癌と感染性疾患に有効な同種異系、既製の細胞治療ワクチンの開発に従事する。同社のImmunePan抗原細胞傷害性療法（インパクト）は癌患者の免疫系を活性化して癌性細胞を認識して殺させる一連の癌関連抗原及び｢gp96｣と呼ばれる免疫アジュバントを送り出すように再プログラムされた遺伝子組換えの被照射ヒト生細胞を送達するために設計されている。同社の主要な製品候補は、｢HS-110｣と｢HS-410｣である。同社はまた乳癌と卵巣癌向けの｢ImPACT｣という治療用ワクチンを開発している。 ヒ―ト・バイオロジクスは開発段階の米国のバイオ医薬品会社。がんや感染症に対応するアロジェニック、およびオフザシェルフ細胞療法ワクチンの開発に注力する。新薬候補には非小細胞性肺がん治療用のHS-110、および膀胱がん治療用のHS-410がある。本社はノ―スカロライナ州。 Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials. |
| 本社所在地 | 801 Capitola Drive Durham NC 27713 USA |
| 代表者氏名 | Jeffrey Alan Wolf ジェフリー・アラン・ウルフ |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 919-240-7133 |
| 設立年月日 | 39600 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2013年 |
| 従業員数 | 19人 |
| url | www.heatbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/htbx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.67771 |
| 終値（lastsale） | 1.88 |
| 時価総額（marketcap） | 43479293.92 |
| 時価総額 | 時価総額（百万ドル） 40.01020 |
| 売上高 | 売上高（百万ドル） 2.98016 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 15.34947 |
| 当期純利益 | 当期純利益（百万ドル） -21.03366 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Heat Biologics Inc revenues increased from $435K to $1.9M. Net loss increased 18% to $7.6M. Revenues reflect Grant and licensing revenue increase from $411K to $1.9M. Higher net loss reflects Research and Development increase of 60% to $6.4M (expense) General and administrative increase of 1% to $3.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.10 to -$1.02. |
HTBXのテクニカル分析
HTBXのニュース
Heat Biologics stock soars 9% on supply contract with Canada for anthrax drug Anthim 2022/04/27 12:51:42 Seeking Alpha
Heat Biologics (HTBX) said its unit Elusys Therapeutics finalized a contract with the Canadian government to deliver anthrax therapy Anthim
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM to the Canadian Government 2022/04/27 12:00:00 Wallstreet:Online
New contract marks the first international sale of ANTHIM and follows recent acquisition of Elusys by NightHawk DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders
Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics 2022/04/20 12:00:00 Benzinga
Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. Nighthawk acquired all outstanding shares of Elusys, which will continue to operate as a wholly-owned subsidiary of NightHawk. No stock or warrants were issued in connection with the acquisition, and Elusys had no outstanding term debt. The strategic acquisition of Elusys significantly expands the Company''s role in the biodefense space, complementing NightHawk''s RapidVax® platform, which is designed to target emerging biological threats.
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics 2022/04/20 12:00:00 Heat Biologics
Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient''s immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces…
Heat Biologics to rebrand as NightHawk Biosciences from next month 2022/04/19 15:49:33 Seeking Alpha
The clinical-stage biotech, Heat Biologics (HTBX), announced on Tuesday that it would change its name to NightHawk Biosciences effective May 03
Heat Biologics stock soars 9% on supply contract with Canada for anthrax drug Anthim 2022/04/27 12:51:42 Seeking Alpha
Heat Biologics (HTBX) said its unit Elusys Therapeutics finalized a contract with the Canadian government to deliver anthrax therapy Anthim
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM to the Canadian Government 2022/04/27 12:00:00 Wallstreet:Online
New contract marks the first international sale of ANTHIM and follows recent acquisition of Elusys by NightHawk DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders
Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics 2022/04/20 12:00:00 Benzinga
Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. Nighthawk acquired all outstanding shares of Elusys, which will continue to operate as a wholly-owned subsidiary of NightHawk. No stock or warrants were issued in connection with the acquisition, and Elusys had no outstanding term debt. The strategic acquisition of Elusys significantly expands the Company''s role in the biodefense space, complementing NightHawk''s RapidVax® platform, which is designed to target emerging biological threats.
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics 2022/04/20 12:00:00 Heat Biologics
Heat Biologics a biopharmaceutical company that develops immunotherapies with the goal of activating a patient''s immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces…
Heat Biologics to rebrand as NightHawk Biosciences from next month 2022/04/19 15:49:33 Seeking Alpha
The clinical-stage biotech, Heat Biologics (HTBX), announced on Tuesday that it would change its name to NightHawk Biosciences effective May 03
Traders cant mares this Stock: Ford Motor Company (NYSE:F), Heat Biologics, Inc. (NASDAQ:HTBX) 2021/07/08 02:19:56 Stock Equity
Ford Motor Company (NYSE:F) with the stream of -1.17% also noticed, India Heat Biologics, Inc. (NASDAQ:HTBX) encountered a rapid change of -3.24% in the last hour of Wednesdays trading session. The post Traders cant mares this Stock: Ford Motor Company (NYSE:F), Heat Biologics, Inc. (NASDAQ:HTBX) appeared first on Stocks Equity .
Traders should take notice on: CommScope Holding Company, Inc. (NASDAQ:COMM), Heat Biologics, Inc. (NASDAQ:HTBX) 2021/06/28 23:32:34 Stock Equity
CommScope Holding Company, Inc. (NASDAQ:COMM) with the stream of -0.42% also noticed, India Heat Biologics, Inc. (NASDAQ:HTBX) encountered a rapid change of -1.52% in the last hour of MONDAYs trading The post Traders should take notice on: CommScope Holding Company, Inc. (NASDAQ:COMM), Heat Biologics, Inc. (NASDAQ:HTBX) appeared first on Stocks Equity .
Heat Biologics Joins Russell Microcap Index 2021/06/28 11:30:00 Wallstreet:Online
DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has been added to the Russell Microcap Index, following the annual Russell indexes reconstitution, effective after the US market opens today, June 28, 2021, according